The development of antiviral strategies to prevent or treat respiratory syncytial virus (RSV) infections is of great importance, especially considering the fact that RSV is one of the most important causes of pediatric respiratory infections. However, despite intense efforts, there is no antiviral or vaccine approved for the prevention or treatment of RSV infections. Several inhibitors, targeting different RSV proteins have been discovered over the past decade. We here review the most important chemical series as well as recent developments in understanding which viral proteins and/or host cell factors are good targets for inhibition of viral replication. In addition, we highlight the current in vitro and in vivo model systems of the disease. A number of molecules are currently in (advanced) preclinical or clinical development. Significant breakthroughs in the field may be expected in the upcoming years. 
RSV burden of disease, epidemiology and transmission
The respiratory syncytial virus (RSV) is a pneumovirus that belongs to the family of the Paramyxoviridae. The virus infects virtually all children by the age of three, making it the most important viral agent causing severe respiratory illness in infants and children worldwide. More specifically, RSV infections are responsible for one-third of acute lower respiratory infection related deaths in infants less than one year of age and are particularly problematic in premature babies as well as in children with underlying cardiac and respiratory problems [1] . The virus causes also significant disease in elderly [2, 3] as well as in transplant recipients.
RSV is transmitted by contact with oral or nasal secretions, causing repeated infections throughout life. An RSV infection elicits both innate and adaptive immune responses, however immunity against the virus is not long-lived. The fusion (F) and attachment (G) surface glycoproteins have the ability to induce neutralizing antibodies, which wane quickly after infection [4] . RSV shows seasonal circulation in more temperate climate regions, with highest detection rates in late fall and early spring, in contrast to tropical regions were RSV is detectable year round, although the latter is not a consistent finding [5, 6] .
Currently, infected patients mainly receive symptomatic treatment consisting of bronchodilators and mucolytic agents, while high-risk young pediatric patients (<29 weeks gestation without chronic lung disease) also receive prophylactic treatment with monoclonal antibodies (Palivizumab) [7] . The observation that a higher viral load on day three of hospitalization was associated with a requirement for intensive care and respiratory failure in children under two years of age indicates there is a potential therapeutic window for the use of antivirals in this patient population [8] . Ribavirin is currently the only small molecule that has been approved for treatment of serious RSV infections, but its use is limited because of side effects, lack of efficacy, difficult route of administration and high cost.
Genetic diversity and genome organization
RSV is an enveloped, non-segmented, single stranded negative sense RNA virus with a genome size of approximately 15.2 kb. The ten genes encode for eleven proteins named NS1, NS2, N, P, M, SH, G, F, M2-1, M2-2 and L. RSV can be divided into two subgroups RSV-A and RSV-B, which contain different genotypes based on the nucleotide sequence of the carboxy-terminal ectodomain of the G protein [9] . A genotype classification system based on a gene segment of 629 bp for RSV-A and 724-762 bp for RSV-B, comprising both the conserved region and the hypervariable regions of the G protein has been developed [10, 11] 
In vivo models using surrogate viruses and non-human primate models
Large animal models of RSV include non-human primates, calves and lamb and their use has been reviewed recently [21, 22] . Briefly, infection of calves with bovine RSV results in severe disease with a pathology and immunological response that is comparable to that of human RSV infections in children [23] . Bovine RSV infection in cattle is responsible for significant economic losses to the farming industry. Intranasal infection of lamb with human RSV results in moderate clinical signs of both the upper and lower respiratory tract. In particular Memphis 37, a clinical strain of human RSV, has been used to infect neonatal lamb and causes a disease that is comparable to that of RSV infections of human infants [24] . Infection of chimpanzee with the human RSV results in only mild disease that is limited to the upper respiratory tract [25] . The bovine, ovine and non-human primate models have advantages of sample collection, anatomical similarity of the respiratory track (non-human primates, sheep) and reliable pulmonary function measurements, but they also have obvious disadvantages. For example, bovine-and ovine RSV are genetically different from human RSV, the use of these animals poses housing and husbandry issues, limited molecular tools are available for these animals and large quantities of inhibitors are needed for such studies. Altogether these disadvantages highlight the need for robust and convenient small animal RSV infection models.
Small animal models using human RSV
Cotton rats are semi-permissive for human RSV infection with both upper and lower respiratory tract infection [26, 27] . Peak pulmonary replication is observed on day 4 post infection with virus clearing from the lungs by day 7 post infection (or earlier). Cotton rats have been widely used for modeling respiratory viral infections and the peak RSV levels are $100 x higher than in mice. Lower respiratory tract infection is already achieved in this model upon intranasal infection with 10 4 plaque-forming-units (PFU) whereas >10 5 PFU is needed in mice. For this reason, the cotton rat model has been the preferred animal model for studying RSV replication and testing antivirals. The pathology associated with RSV challenge in cotton rats consists of only mild to moderate bronchiolitis or pneumonia. The model was used intensively to study how a formalin-inactivated RSV vaccine candidate caused enhanced respiratory disease following natural RSV infection.
However recent results highlight that also non-viral products from the vaccine and challenge preparations give rise to enhanced disease, which limits the validity of this model [28] . The cotton rat model has also been modified, using a high-dose cyclophosphamide as immunosuppressive therapy, to replicate the persistent RSV pneumonia seen in stem cell transplant recipients. In this model RSV replication remains high for at least 16 consecutive days allowing the study of therapeutic interventions [29] . Also inbred laboratory mouse strains have been explored intensely as a model for RSV infection [21] . Compared to the cotton rat model a very high intranasal inoculum (10 5 to 10  7 PFU per mouse) is often administered, in order to have some signs of lower respiratory tract infection, while the peak levels on day 4 post infection in the lungs are rather low (10 4 PFU/g tissue). As in the cotton rat model the virus is eliminated by day 7 post infection. Several attempts have been made to improve the model by immunosuppression. A 5-day cyclophosphamide pretreatment of BALB/C mice resulted only in a moderate increase in virus titers (2x) and virusinduced pathology [30] . The use of nude mice, which are athymic BALB/c mice that cannot generate mature T-lymphocytes, turned out to be more successful [31] . Infection of these animals results in peak levels that are $100 fold higher than those in BALB/c mice and the virus remains detectable for at least 9 days after infection. Also more severe inflammation of the airways was observed in the nude mice compared to immunocompetent BALB/c mice.
More recently the effect of infection with several RSV strains, including low-passage clinical isolates, was explored in the BALB/c mice model [32] . This revealed that infection with one particular isolate (strain 2-20) was associated with more significant lung dysfunction, as measured by increased breathing effort, airway resistance and mucin expression. Interestingly the viral load in the lungs of mice infected with these isolates was comparable or even lower compared to mice infected with the laboratory strain A2. Another RSV strain (Line 19) results in an increased mucus production and pathogenicity compared to the infection with strain A2. Line 19 is an older RSV strain that has been intensively passaged in laboratory cell lines. The virulence of Line 19 was linked to the F protein through the studies of chimeric strains and more recently mutations in this protein have been explored for their role in disease pathology [33] . This shows that increased fusogenicity of the F protein of strain Line 19 correlates with many aspects of the pathology but not with the induced high levels of airway mucin expression.
Immunocompromised ferrets are also a potential model to study human RSV replication. In a recent study an intratracheal inoculation (10 5 , that differs in 13 amino acids from Palivizumab; it has a greater affinity and increased in vitro potency [36] . Despite promising results in mice, the development was discontinued when treatment of infants hospitalized with respiratory syncytial virus infection did not decrease viral load or severity of illness [37, 38] . Other companies developing anti-RSV antibodies include Ablynx and Regeneron. Ablynx completed phase 1 studies (NCT01483911 and NCT01875926) for its nanobody administered via pulmonary inhalation, while Regeneron is more advanced in the development of a fully human monoclonal antibody (REGN2222) that also targets the F protein and is intramuscularly administered. Its efficacy and safety, for the prevention of medically attended RSV infection in preterm infants is being evaluated during a phase 3, randomized, double-blind, placebo-controlled study (NCT02325791). The estimated primary completion date of the study is July 2016 [39] .
Fusion inhibitors
The entry of RSV into host cells involves two membrane proteins, a trimeric fusion (F) glycoprotein, and an attachment (G) glycoprotein. More specifically, cell entry is mediated by the class I viral F protein in response to binding of a host receptor by the attachment protein. During posttranslational processing, the fusion peptide of F is released and, upon receptor-induced triggering, inserts into the host cell membrane. As F undergoes a dramatic refolding from its metastable pre-fusion to the stable 6-helix bundle (6HB) post-fusion conformation, the host and viral membranes are brought together, allowing fusion and entry of the viral ribonucleoprotein complex [40, 41] . The RSV G-protein is not essential for viral entry, in contrast to the attachment proteins of other paramyxovirinae, although it does contribute to the efficiency of entry [16, 42] . Thus far, one compound targeting the G-protein of RSV has been described (MBX-300, Microbiotix, previously called NMSO3). It is thought to inhibit attachment by blocking electrostatic binding between the viral envelope and cell membrane [43] . Safety and efficacy of this sulfated sialyl lipid compound were already demonstrated in animal models. In contrast to the Gprotein, the F-protein is critical for entry and is the main target for antivirals currently under development (Fig. 1) . [44] . In vitro, drug-resistant selected variants exhibit significant cross-resistance to both inhibitors and carry various single amino acid substitutions in two distinct regions of the viral F protein, the heptad repeat 2 (HR2; mutations D486N, E487D, and F488Y), and the intervening domain between HR1 and HR2 (mutation K399I and T400A) ( Fig. 2A) . These different ''escape hotspots" were shown to be located in close proximity to each other in the pre-fusion confirmation [45] . Altogether, different studies have indicated that VP-14637 and JNJ-2408068, as well as GS-5806, BMS-433771, P13, C15 and BTA-C585, interfere with RSV fusion through a mechanism involving a similar interaction with the F protein. Studies have shown that the central amino acid in the middle alpha helix of the pre-HRA domain, Y198, is a critical binding site for these compounds and an essential amino acid for the correct functioning of the F protein [46, 47] . More recently, in addition to this direct mechanism of escape, indirect escape has been suggested, were destabilizing mutations in RSV F protein lower the barrier for prefusion F triggering, resulting in a decreased window of opportunity for the inhibitors to bind [45] . However, Battles and colleagues reported that this decreased stability and enhanced fusogenicity are not general properties of resistant viral strains [46] . 4.1.2.1.1. GS-5806. GS-5806 (Presatovir, Gilead Sciences) is an allosteric inhibitor of the F-protein that blocks viral entry. It is the first of the orally available drug candidates for which a phase 2 clinical trial has been completed. GS-5806 was found to be active in vitro to a wide range of RSV clinical isolates [48] . In this study RSV strains resistant to GS-5806 that were generated in vitro were shown to carry mutations L138F and F140L/N571I in the F protein for RSV-A and F488L or F488S for RSV-B ( Fig. 2A) . In a phase 2a trial (NCT01756482) study participants (healthy volunteers experimentally infected with RSV) were divided in seven cohorts and the compound was first administered within 5 days after infection (but before the onset of symptoms). Cohorts 1-4 received a first dose of 50 mg of GS-5806 and then 25 mg daily for the next 4 days, cohort 5 received a first dose of 50 mg and then 25 mg daily for the next 2 days, cohort 6 received one 100-mg dose, and cohort 7 received a first dose of 10 mg and then 5 mg daily for the next 4 days. GS-5806 treatment reduced viral load in nasal washes (adjusted mean, 250.7 vs. 757.7 log 10 plaque-forming-unit equivalents [PFUe] Â hours per milliliter; P < 0.001) and severity of symptoms of the RSV infection (lower area under the curve for the change from baseline in symptom scores (adjusted mean, À20.2 vs. 204.9 Â h; P = 0.005)). Such beneficial effect had never before been demonstrated with other small molecule RSV inhibitors [49] . The adult subjects enrolled in this phase 2a study showed treatment-emergent GS-5806 resistant RSV variants in which the F140L and T400I mutations were most frequently observed ( Fig. 2A ) [50] . The fact that a mutation in the hotspot around Fresidue 400 (D401E) has shown to remain its pathogenicity in a mouse model raised concerns that mutations in this hotspot could become prevalent in circulating RSV strains if this compound would be used in the clinic [45] . Gilead is currently recruiting for placebo-controlled phase 2 studies to study the safety and efficacy of GS-5806 in patients that have been naturally infected with RSV and who have been hospitalized with acute respiratory symptoms (NCT02135614). The efficacy and safety will also be studied in high risk patients such as lung transplant recipients with RSV infection (NCT02534350) and in hematopoietic cell transplant recipients that suffer from infections of the upper and lower respiratory tract (NCT02254408 and NCT02254421 respectively).
MDT-637
. VP-14637 (ViroPharma/Gilead) is a reformulation of MDT-637 for improved aerosol delivery. VP-14637 demonstrates antiviral activity against RSV-A strain A2, with an EC 50 value of 1.4 nM. It binds directly to the F protein and interferes with fusion of the virus with the host cell (EC 50 of 5.4 nM observed in RSV-mediated cell fusion assay). The interaction with F involves both heptad repeat domains of the protein trimer [51] . The compound also has in vitro antiviral activity (EC 50 1.72 nM) against 75 RSV clinical isolates (both RSV-A and RSV-B) [48] . During this study in vitro resistance mutations in de F-gene were selected using strains RSV A2 (F488I or T400I/N517I) and RSV-B 18537 (L141V) (Fig. 2A) . In vivo tests in cotton rats using divided-dose aerosol of only 126 lg drug/kg and starting on day 1 after RSV-A or RSV-B challenge resulted in significantly lower mean pulmonary RSV titers and reduced histopathology scores as compared to mock-or vehicle-treated animals [52] . Preclinical studies revealed that the compound could be delivered in both the upper and lower respiratory tract [53] . Phase 1 study data were presented in abstract form in 2012 [54] . A Phase IIa trial of VP-14637 (EudraCT Number: 2012-001107-20) in 2012 in healthy subjects challenged with RSV was initiated but was halted for unknown reasons.
JNJ-2408068.
A benzimidazole derivative, JNJ-2408068 (R-170591), was reported with an EC 50 of 0.16 nM against RSV-A Long strain, which is roughly 100,000 fold more potent that the activity of ribavirin (15 lM) [55] . Antiviral activity was confirmed for subgroup A and B clinical isolates of human RSV and for a bovine RSV isolate. The compound did not inhibit the growth of representative viruses from other Paramyxovirus genera. One resistant virus isolate was raised showing single point mutations in the F-gene (D486N) (Fig. 2A) . JNJ-2408068 also inhibit the release of proinflammatory cytokines IL-6, IL-8 and Rantes from RSV-infected A549 cells. This compound has long tissue retention times in several species (rat, dog, and monkey), because of its aminoethylpiperidine moiety, which created concern and halted further development [56, 57] .
is an optimized derivative of JNJ-2408068 that lacks the long tissue retention of its predecessor [55, [57] [58] [59] . It prevents virus-cell as well as cell-cell fusion in vitro. TMC353121 inhibits fusion by disturbing the 6HB post-fusion formation [60] which is formed by intramolecular interactions of trimeric-coiled coil HR1 with 3 anti-parallel oriented HR2 [61] . HR1 and HR2 associate with each other trough a hydrophobic cavity which is considered to be the potential drug-binding site [62, 63] . TMC353121 was shown to directly interact with both HR1 and HR2, stabilizing their interaction in a different 6HB conformation than its natural one. More and more data indicate another potential mechanism of action which involves antagonizing fusion by preventing triggering of the metastable pre-fusion confirmation of the F-protein [46] . TMC353121 has also been studied in in vivo models, including mouse [64] , rat [65] and nonhuman primates [59] . In BALB/c mice that had been infected intranasally with RSV A2 and treated with TMC353121 (at dose ranging from 0.25 to 10 mg/kg) viral load in the lung was reduced if treatment was initiated within two days of infection. Efficacy testing of TMC353121 in the RSV cotton rat and African Green Monkeys models revealed a reduction in viral load in a dose-dependent manner.
4.1.2.1.5. BMS-433771. BMS-433771 is a small molecule RSV inhibitor with an average in vitro EC 50 of 20 nM against RSV-A and RSV-B laboratory strains and clinical isolates [66, 67] . BMS-433771-resistant viruses were found to carry single amino acid mutations (F140I, V144A, D392G, K394R, D489Y) in the F1 domain of Fprotein ( Fig. 2A) . The compound was also shown to be efficacious in two rodent RSV infection models (BALB/c mice and cotton rat models) when dosed orally prior to infection, suggesting it might be usefully prophylactically but not therapeutically [68] . Direct affinity labeling studies indicate that the compound binds the hydrophobic cavity where HR1 and HR2 associate to form a six helical coiled-coil bundle (or trimer-of-hairpins), and presumably interferes with the functional association of these heptad repeats [67, 69] . However, as for other RSV entry inhibitors, another mechanism of action, such as blocking the prefusion RSV F trimer has been suggested for BMS-433771 [45] . Fig. 2A) . Activity could be demonstrated in the RSV cotton rat model, where BTA-C585 was orally dosed at 25, 50, 100, 250 mg/kg two hours prior to infection with 10 4 pfu/mL of RSV-A strain Long, showing a 1.0-3.0 log 10 reduction in the viral mRNA detected in the lung five days post infection [70] . Two studies in healthy volunteers have been finished (NCT02558413, NCT02668367), but thus far no results have been made public. Recruitment to test safety, efficacy as well as pharmacokinetics in a RSV viral challenge study is currently ongoing (NCT02718937).
4.1.2.1.7. P13 and C15. The benzenesulfonamide-based compound P13 and the diazepane-based compound C15 were reported to inhibit RSV-A strain A2 replication with EC 50 values of 0.11 lm (P13) and 0.13 lM (C15) [71] . Drug-resistant variants were selected for both P13 and C15 and were shown to carry amino acid substitutions in the F protein, more specifically D489G (for C15 resistant strain), T400I and N197T (for P13-selected virus variants). These three mutations are located in the HR1-region (N197T), HR-2 region (D489G) and in the cysteine-rich domain of the F1 subunit region (T400I) (Fig. 2A) . These are regions where resistance associated mutations to the compounds BMS-433771, VP-14637 and TMC353121 have also been detected, indicating a similar (perhaps not identical) mode of action for these compounds. randomized, double-blinded, placebo-controlled study the antiviral activity, safety, and pharmacokinetics of repeated doses of orally administered JNJ-53718678 were studied against RSV infections in healthy adults who had been challenged with RSV. This study was completed in September 2015 (NCT02387606). Currently a study in infants hospitalized because of an RSV infection, is planned (NCT02593851). Participants are also being recruited to a study to assess the effects of Itraconazole and Rifampicin on the single-dose pharmacokinetics of JNJ-53718678 in healthy adults (NCT02729467).
AK-0529
. AK-0529 (Ark Biosciences) is an RSV inhibitor for which no structure nor results have been published to date. In a randomized, double-blinded, placebo-controlled phase 1 study of orally administered AK-0529, safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses were evaluated. The compound was well tolerated, with an excellent safety profile [72] . At the moment two other clinical studies have been registered to be carried out in Australia (NCT02460016 and NCT02654171). The first trial is a Phase 1b study in which also the potential anti-viral effect of single dose of AK0529 will be studied in infants hospitalized with an RSV infection, the second trial is a phase 2 study. 50 values around 20 nM) [73] . The compound was shown to inhibit binding as well as fusion of RSV with cells and showed to be resistant to viruses showing a mutation at position 446 of the F-protein ( Fig. 2A ) [74, 75] . This bi-phenyl analog of CL-309623 is also potent in different animal models when delivered intranasally [76, 77] . More specifically, 1.3 mg/kg administered 2 h prior to virus challenge of mice reduced virus lung titers by 1.5 log 10 . In cotton rats a dose of 10 mg/kg reduced the lung viral titer by 2.6-3.2 log 10 when given at a same prophylactic dosing regimen. In African Green Monkeys infected with RSV, RFI-641 when given by inhalation using a nebulizer reservoir at a dose of 15 mg/ml 2 h prior to infection caused a 3.4 log 10 reduction in viral load (In bronchial lavage 7 days post infection). At a 6 mg dose, viral titers were significantly lower on days 4-9 (peak viral load) with a 1.8-3.4 log 10 reduction. In addition to being active when given prophylactically, the compound was also shown to be active therapeutically in the monkey model (when the first dose given 24 h after infection in the monkey model and continued once per day for 8 days) [76] . (Fig. 3) 
RFI-641. RFI-641 (Pfizer) is a small dendrimer-like compound with potent in vitro activity against both RSV-A and RSV-B laboratory strains and clinical isolates (EC

Non-entry as target
L-protein inhibitors
All negative-strand RNA viruses encode a L (''large") protein that has several biochemical activities. This protein functions as the RNA-dependent RNA polymerase that replicates the viral genome and transcribes mRNAs. The L-protein is also a capping enzyme that guanylylates and methylates the 5 0 end of the viral mRNA transcripts. Moreover it has poly-adenylation activity aimed at protecting the 3 0 -ends of the viral mRNAs (for a recent summary [78] ). Viral polymerases remain the leading therapeutic targets for treating viral infections. Different polymerase inhibitors have been approved for infections with herpes, hepatitis B, hepatitis C viruses as well as HIV and have been crucial in improving the quality of life of these patients.
4.2.1.1. Ribavirin. Ribavirin is the only licensed drug for the treatment of RSV. Because of toxicity (including bone marrow suppression and potential carcinogenicity and teratogenicity) and marginal efficacy it is not routinely used in infants hospitalized with RSV infection. In addition it is difficult to administer (aerosol) and carries a high cost [79] .
Several mechanisms of action for the antiviral activity of ribavirin have been purposed including inhibition of the cellular enzyme inosine 5-monophosphate dehydrogenase (IMPDH), immunomodulation of antiviral innate and cellular responses, chain termination during viral RNA synthesis, inhibition of viral mRNA capping and accumulation of mutations in viral genomes [80] . These have been discussed extensively elsewhere and will not be addressed here.
ALS-008176:
Inhibition of RSV polymerase by a nucleoside analog chain terminator. ALS-008176, a prodrug of the novel RSV replication inhibitor ALS-008112 (Alios Janssen), is a cytidine nucleoside analog. Upon oral administration ALS-008176 is metabolized in the plasma to ALS-008112, which is taken up by different cell types including those of the respiratory track. Intracellular ALS-008112 is further metabolized by cellular enzymes to the active metabolite ALS-008112-5 0 -triphosphate which is the active inhibitor of the RSV polymerase. In vivo studies showed that this active metabolite has a long intracellular half-life ($29 h) in the lung of monkeys. Similarly, biochemical studies revealed that it is a potent and selective inhibitor of RSV RNA-dependent RNA polymerase activity (K i of 0.09 lM), via a classic chain termination mechanism. Two independent in vitro experiments identified resistant virus population in which 4 mutations (M628L, A789V, L795I and I796V) in the L-protein were found together on the large majority of the genomes sequenced (Fig. 2B) . The last three of these mutations are in close proximity to the catalytic motif C ( 810 GDNQ 813 ) that is responsible for nucleotide incorporation by paramyxovirus RNA polymerases. In vitro experiments also show that ALS-008112 is a broad-spectrum inhibitor of paramyxoviruses as it shows significant activity on parainfluenza virus and even vesicular stomatitis virus (Rhabdovirus family). This is in accordance with the conservation of the active site catalytic motif C of these RNA polymerases. No activity was detected on negative strand RNA viruses beyond the paramyxo-and rhabdovirus families, nor was activity noted against any of the tested positive strand RNA viruses [81] .
ALS-008176 is currently being actively evaluated in clinical trials. The results of a first human challenge study have been reported [82] . In this study healthy adult volunteers were challenged with 4 log 10 PFU of the RSV-A Memphis 37b challenge virus. Participants were monitored twice daily for RSV infection by RT-PCR assay on nasal washings and upon qualitative detection of RSV or on the morning of day 6, whichever occurred first, participants were randomized and received ALS-008176 or placebo. Three ALS-008176 dosing regimens were evaluated over the three study periods: a single loading dose of 750 mg followed by 9 maintenance doses of 500 mg, a single loading dose of 750 mg followed by 9 maintenance doses of 150 mg and 10 doses of 375 mg. These doses were administrated every 12 h over a period of 5 days and RSV load in nasal-wash samples was measured twice daily until day 12 and once on study days 16 and 28. In this study ALS-008176 treatment was not associated with any serious adverse events or premature discontinuation of the study in any of the participants. Absolute reductions in viral load in the treated group was apparent within 12 h after start of treatment and the mean time to nondetectability for RSV RNA ranged from 1.3 to 2.3 days (compare with 7.2 days for the placebo group). The clearance rate of RSV RNA (the slope of the viral load) was most rapid in the two regimens that incorporated a loading dose and the clearance rates for all three regimens were significantly more rapid during the first 48 h than the rates for placebo. In addition, the severity of RSV disease, as assessed by means of symptom scores and quantity of nasal mucus production, was significantly lower in the three ALS-008176 treatment groups than that in the placebo group. None of the resistance associated mutations found in vitro could be detected in any of the samples from this in vivo study. In conclusion this challenge experiment shows that a nucleoside inhibitor can have a significant beneficial effect on RSV infections in humans in an experimental setting. However, this study design is significantly different from a clinical setting where the patients are small children with no or less preexisting immunity presenting with severe symptoms. For this purpose, clinical trials in infants hospitalized with RSV infection are currently ongoing (NCT02202356).
BI-D inhibits the viral mRNA guanylylation activity of the L-protein. BI-D (Boehringer Ingelheim
is a molecule that inhibits the in vitro replication of RSV-A and RSV-B in the submicromolar range and a selectivity index of $400 [83] . Other groups have reported a significantly lower selectivity ($30x) [84] . The compound was originally identified as a RSV polymerase inhibitor by screening compounds in a biochemical assay [85] . Further analysis revealed that the molecule does not inhibit the initiation or elongation of viral RNA transcription but that it causes premature abortion of transcription leading to increased amounts of short RNA species (<50 nt). Strains, selected to be resistance against BI-D, were shown to carry mutations at positions 1269, 1381 and 1421 of the L-protein (Fig. 2B) More recent analysis of the positions of the above resistance associated mutations in the context of the VSV L protein structure domain showed that these positions are within the motifs responsible for GDP-polyribonucleotidyltransferase (PRNTase) activity [86, 87] . This PRNTase activity is responsible for the capping of the viral mRNA's. The 3D structure of the VSV-L protein also provides hints as to how capping and mRNA elongation could be linked. During early transcription the PRNTase active site of the capping domain is directed toward the polymerase active site. When the transcript reaches a certain length its 5 0 end reaches the capping domain and the PRNTase activity adds the cap to the viral mRNA. Only then the capping domain is displaced releasing the 5 0 end of the viral mRNA allowing further elongation of the viral mRNA and further methylation of the cap. If the capping reaction is inhibited and the capping domain is not displaced then the short mRNA cannot be elongated further and only short uncapped viral mRNA's can be produced [87] .
In vivo efficacy studies in RSV-infected mice showed that compound D reduced the infectious viral load in mice lung by 0.6 log upon intranasal administration at 0.4 mg/kg/day [83] . To our knowledge, clinical trials have not been initiated. As the capping of viral mRNA is a unique biochemical mechanism, which is clearly distinct from the host cell capping machinery, this process remains a promising target for antiviral drug discovery [78] .
AZ-27:
A non-nucleoside L-protein inhibitor. AZ-27 (Astra Zeneca) is a follow-up of YM-53403, which was discovered in a CPE-based screening effort, that inhibits RSV-A replication (both lab strains and clinical isolates) with EC 50 values in the 10-40 nM range. The activity against RSV-B is much less pronounced (EC 50 $ 1 lM). The molecule retains in vitro activity when added after viral entry and is as well effective in a replicon assay, which indicates an inhibition of the intracellular replication phase of the virus. In all independently selected drug-resistant variants mutation Y1631H was identified in the L-gene (Fig. 2B) . The inhibitor is not cross-resistant with BI-D, ribavirin or RSV604 (see infra). Based upon an alignment of the RSV and VSV L-protein, Y1631 is located in a linker region between the connector domain, which connects the capping domain and the methyltransferase domain [87] . The nearby amino acid sequences are 100% conserved in the L protein across RSV A and B isolates, while differing from those observed in other paramyxoviruses analyzed. Subsequent investigations have shown that AZ-27 differentially inhibits the different RSV polymerase activities [88] , i.e. AZ-27 has a more potent inhibitory effect on the synthesis of transcripts from genes at the 3 0 end of the genome than on those from the 5 0 end, and this follows the same pattern of activity observed on RSV A and B as in the cell based assay. More in detail the compound inhibits the initiation of de novo RNA synthesis at the promoter, which prevents both transcription and RNA replication. Analysis of small RNA products shows inhibition of the formation of even the first phosphodiester bond in RNA synthesis. It is hypothesized that AZ-27 impairs the ability of the RSV RNA-dependent RNA polymerase (RdRp) to adopt a particular structural form required for initiation of RNA synthesis [88] . Position Y1631 is in this model seen as part of a hinge region important for RdRp flexibility and dynamic transitions between a state of initiation and elongation of RNA synthesis. There are so far no studies reported that investigated whether AZ-27 affects the PRNTase and/or MTase functions of the RdRp.
N-protein targeting RSV inhibitor
The viral nucleoprotein N tightly binds the RSV genomic RNA to form a left-handed helical N-RNA ribonucleoprotein complex (RNP). This RNP is the template for transcription and replication by the RdRp (L protein). Viral RNA synthesis is mediated by the viral Phospho-(P) protein which is a multifunctional protein that interacts with L and N. It allows efficient and specific recognition of the RNP template by the RdRp and subsequent RNA polymerization. In this way P permits the continued contact between the RdRp and the RNP as the RdRp progresses. The detailed dynamics of N, P, L and viral RNA interactions during viral RNA synthesis are not fully understood but different observations points toward the following model. The N protein consists of a N-and C-terminal domain (NTD, CTD) linked with a hinge region. Intermolecular interactions between the different N proteins and the viral RNA, located in the hinge region between the CTD and NTD, are sufficient to form the helical RNP complex. The P protein is multimeric and interacts with its C-terminal peptide in a hydrophobic pocket in the N-NTD. This causes the N-protein hinge region to open up and allow access of the L protein to the viral RNA. As the P protein is multimeric the complex will interact with more N-proteins at the same time and in that way release the RNA template along multiple sequential N-proteins. As the L-protein translocates during RNA synthesis existing N-P interactions will continuously disappear while new ones are formed. In this way the viral polymerase complex can crawl further along its template. In addition to viral proteins several host factors have been proposed to be involved in this complex mechanism of viral RNA synthesis [89] . RSV604 inhibits both viral RNA synthesis and the infectivity of released virus. Inhibition of RNA synthesis is cell-line dependent, as shown in infected cells and viral replicons (i.e. the effect is observed in HeLa but not in BHK cells). Using surface plasmon resonance it was demonstrated that the N protein is indeed the target of the molecule. The cell-type dependent antiviral activity may suggest that also host factors are involved in the mechanism of actions. This may also be in line with the location of the RSV604 associated resistance mutations, which is on the surface of the N-protein and thus exposed [91] .
In a Phase I study orally administered RSV604 was shown to be safe and well tolerated in healthy volunteers. A loading dose of 600 mg and subsequent dosing at 450 mg/day resulted in a trough (Cmin) concentrations above the EC 90 throughout the study [92] . A proof-of-concept trial was then organized in hematopoietic stem cell transplant patients, where RSV infections are an important health risk. However this trial seemed to have been very challenging for several reasons such as the limited number of patients, their complex underlying conditions and the seasonality of the virus. During the trial most patients had lower RSV604 drug levels than anticipated and no significant difference in viral load with placebo could be observed. Only in patients with RSV604 plasma levels above the EC 90 a drop in viral load was reached [93] .
Targeting the N-P protein-protein interaction
Recently the X-ray structures of the N-NTD in complex with Cterminal peptides of P-protein were solved [94] . This gained detailed insight into the N-NTD:P-CTD interaction and how the terminal residues of the P protein penetrate deeply into a pocket in the N-protein. As this N-P interaction is crucial for viral RNA synthesis this pocket was considered a promising target for interfering with virus replication. An in silico screening campaign and subsequent structural studies identified a chemical series of compounds with a 1-benzyl-1H-pyrazole-3,5-dicarboxylate (BPdC) scaffold that bind this pocket P-CTD. Experiments using surface plasmon resonance demonstrated competition between the C-terminal peptide of P and the BPdC molecules. Preliminary cell-based antiviral experiments with the highest-affinity compound, M76, did not show significant inhibitory activity. This was not a surprise as the molecule has two negatively charged carboxylates that most likely prevent cellular uptake. A prodrug was made in which the carboxylates were shielded by a pH sensitive moiety that is released by hydrolysis in the cytosol. This prodrug showed some antiviral activity but with a very limited selectivity index (EC50 $ 122 lM, SI $ 2). With this very limited selectivity it will be very challenging to prove that the activity observed in cell culture is indeed linked to the proposed mechanism of action. No activity could be detected on the in vitro replication of VSV demonstrating the specificity of the approach. Note that in the family of rhabdoviruses (like VSV) it is the N-terminal region of P that binds N [89] .
Targeting the SH-protein
Together with the F and G protein, the SH protein (smallhydrophobic protein) is one of the tree envelop proteins of RSV. While F and G are clearly involved in entry in the host cell the role of SH is less clear. The SH protein is a viroporin, a family of small hydrophobic proteins encoded by several animal viruses that, upon oligomerization, form hydrophilic pore in the virus infected cell. They seemed to have a wide variety of functions in the viral life cycle, often associated with immunomodulatory activity.
A role of SH in RSV pathogenesis was suspected early as strains lacking SH behave similar to the wild-type in cell culture (replication kinetics, plague formation. . .) but showed severe attenuation upon infection of chimpanzee [95] . In mice these strains replicate to the same extent as WT RSV in the lungs but significantly less in the upper respiratory track [96] . This attenuation could be due to an increased IL-1b response to RSVDSH in vivo leading to the hypothesis that the pore structure of the SH protein counteracts the activation of the NLRP3 inflammasome by ionic changes [97] .
Because of this attenuation deleting the SH gene is being explored for vaccine approaches. In addition targeting the SH protein may open up novel antiviral therapies. Recently pyronin B was identified as an inhibitor of the pore function of SH in a biochemical screening assay. Detailed biophysical characterization indicated that the molecule binds SH at the lipid-facing side of the TMa-helices and not into the pore lumen. This indicates an allosteric mechanism of inhibition similar to other viroporin inhibitors (rimantadine, the influenza M2 inhibitor). Interestingly the proposed binding site for pyronin B on SH is highly conserved in human RSV strains. Cell-based experiment demonstrated an antiviral activity of the molecule (EC50 $100 nM) although cellular toxicity or any other potential effect of the molecule on the host cell was not addressed in this study [98] .
Targeting the M2-1 protein
The RSV M2-1 protein (194 amino acids) is a homotetrameric transcription processivity factor that binds in a competitive manner to RNA and the P protein via its core domain. It prevents premature termination of transcription both intra-and intergenetically, making the M2-1 protein essential for the efficient processing of viral RNA during the viral lifecycle [99] [100] [101] [102] [103] . In vitro experiments have shown that M2-1 binds preferentially to positive-sense viral gene end and poly-A sequences [100, 104] however, the exact mechanisms by which M2-1 improves transcription efficiency is not fully understood.
In a recent study it was reported that cyclopamine (CPM) is as a potent inhibitor of RSV infection both in vitro as in vivo [105] . CMP is well characterized as an antagonist of the smoothened protein (Smo), playing a role in embryonic development, cell differentiation and tumorigenesis [106, 107] . However, the inhibition of RSV is mediated through specific inhibition of M2-1-mediated RSV transcription and acts independently of the Smo receptor. A resistance mutation was found in three independently generated CPM-resistant RSV strains at position 151 (R151K), which is located in a region previously described for its role in RNA and P binding [100, 101] .
Targeting host factors
As the human genome is much more stable than that of viruses, targeting an essential host factor in the viral replication cycle has been proposed as an alternative strategy to develop prophylaxis or therapy for RSV infections. A major challenge of such approach is to avoid undesired off-target effects or other toxicity.
Potential host factor targets for treatment or prophylaxis include some of the tentative RSV receptors, co-receptors or co-factors, such as the fractalkine receptor CX3CR1 [108, 109] , glycoproteins/ heparin [110] , intercellular adhesion molecule (ICAM-1) [111] , annexin II [112] , toll-like receptor 4 [113] , Akt [114] , and nucleolin. Substantial efforts have been made in exploring the potential of the latter as a target for inhibition of RSV replication. It is an essential protein found in all cells, which has been identified by different techniques (including a virus overlay protein binding assay, mass spectrometry and immunoprecipitation) as a potential cellular receptor for RSV [115] . Based on antibody binding epitopes studies, a potential RSV-F protein-nucleolin interaction site may occur around amino acids 429-437 (antigenic site IV), which is located in the apex of the F protein [116] [117] [118] . An RSV receptor antagonist, AS-1411, is a guanine-rich oligonucleotide that was originally developed for cancer treatment and targets nucleolin on cell surfaces [119] . The ability to inhibit RSV in vivo has been demonstrated in mice, which showed that AS-1411 given intranasally (50 mg/kg) 4 h prior to RSV challenge reduced the lung levels of the virus by 50% on day 4 post infection [120] .
Final remarks
RSV remains an important pathogen in young children as well as in the elderly. No vaccines or antivirals are available to prevent or treat RSV infection Here we reviewed the progress made on several chemical series that inhibit RSV replication with a wide variety of molecular mechanisms of action. Many of the RSV proteins have now been studied functionally and structurally, some in the presence of small-molecule inhibitors. Recently convincing efficacy of both a fusion and polymerase inhibitor have been demonstrated in phase 2a clinical studies (in healthy volunteers challenged with the virus). These studies are also paving the way for the development of yet other RSV inhibitors. We are now at a turning point in RSV antiviral drug discovery as the first phase 2 trials with novel small molecules in small children are being performed. This brings hope that the first generation anti-RSV drugs for this patient population may get approved within the next few years. A continued effort is needed to ensure the successful development of a second generation of RSV inhibitors, ideally with a different resistance profile.
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